Heart failure & cardiomyopathies

Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity

JACC Heart FailPublished Cost-effectiveness analysis

Authors' conclusion

Tirzepatide seems to be a cost-effective treatment option for patients with HFpEF and obesity in the United States.

Study context

Population
Patients with heart failure with preserved ejection fraction (HFpEF) and obesity in the US; model inputs from the SUMMIT trial
Comparison
Tirzepatide vs standard care alone
Outcome
Incremental cost-effectiveness ratio
Follow-up
20-year time horizon
Methodological detailsMarkov state-transition model, 20-year time horizon, 3% annual discounting, deterministic and probabilistic sensitivity analyses, 10,000 Monte Carlo simulations
  • Markov state-transition model
  • 20-year time horizon
  • 3% annual discounting
  • Deterministic and probabilistic sensitivity analyses
  • 10,000 Monte Carlo simulations

Main finding

As reported in the abstract

ICER
GroupQuality-adjusted life years (QALYs)Total lifetime costs
Tirzepatide7.27 (95% UI: 3.20-13.70)$131,686 (Q1-Q3: $113,005-$150,445)
Standard care6.63 (95% UI: 3.69-11.0)$87,082 (Q1-Q3: $70,866-$105,268)

Quality-adjusted life years (QALYs)

Tirzepatide7.27 (95% UI: 3.20-13.70)
Standard care6.63 (95% UI: 3.69-11.0)

Total lifetime costs

Tirzepatide$131,686 (Q1-Q3: $113,005-$150,445)
Standard care$87,082 (Q1-Q3: $70,866-$105,268)
ICER, tirzepatide vs standard care
$70,297 per QALY gained

Further findings

Total QALYs

OutcomeTirzepatideStandard care
Total lifetime costs$131,686 (IQR $113,005-$150,445)$87,082 (IQR $70,866-$105,268)

Probabilistic sensitivity analysis

Tirzepatide cost-effective in simulations
>50%
Probability of cost-effectiveness
51%

Deterministic sensitivity analysis

Model most sensitive to mortality rates and health state utilities

Original publication

Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity. JACC Heart Fail. Published 20 April 2026. doi:10.1016/j.jchf.2026.103060

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.